deltatrials
Completed PHASE3 NCT00007683

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)

Sponsor: Bristol-Myers Squibb

Conditions Heart Failure
Interventions Aspirin Clopidogrel 75 Warfarin titrated to an INR of 2.5-3.0
Updated 7 times since 2017 Last updated: Jun 14, 2011 Started: Oct 31, 1998 Primary completion: Jul 31, 2003 Completion: Dec 31, 2004

This PHASE3 trial investigates Heart Failure and is currently completed. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Aug 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Sanofi-Synthelabo
  • US Department of Veterans Affairs
Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada, Albany, United States, Ann Arbor, United States, Atlantis, United States, Augusta, United States, Barnsley, United Kingdom, Bay Pines, United States, Bedford, United States, Belfast, United Kingdom, Biloxi, United States and 119 more location s